TPG to take Immucor private

Private equity group TPG Capital will take US diagnostics firm Immucor private in a near $2bn deal that could give the company's niche blood-testing products a more global profile. Immucor has been seen as a potential target because of its unique technology that automates the identification of blood types – a process that was earlier done manually. The deal follows a flurry of private equity-backed acquisitions, which have risen about 42 per cent from a year ago.